Aims: To explore healthcare professionals' perceptions and experiences of take-home naloxone initiatives in acute care settings to gain an understanding of issues facilitating or impeding dispensing.
Design: Systematic literature review.
Data Sources: Cochrane, MEDLINE and CINAHL were searched from 15/03/2021 to 18/03/2021, with a follow-up search performed via PubMed on 22/03/2021. The years 2011 to 2021 were included in the search.
Review Methods: A systematic literature review focused on qualitative studies and quantitative survey designs. Synthesis without meta-analysis was undertaken using a thematic analysis approach.
Results: Seven articles from the United States of America (5), Australia (1) and Canada (1) with 750 participants were included in the review. Results indicate ongoing stigma towards people who use drugs with preconceived moral concerns regarding take-home naloxone. There was confusion regarding roles and responsibilities in take-home naloxone dispensing and patient education. Similarly, there was a lack of clarity over logistical and financial issues.
Conclusion: Take-home naloxone is a vital harm reduction initiative. However, barriers exist that prevent the optimum implementation of these initiatives.
Impact: What is already known: Deaths due to opioid overdose are a global health concern, with take-home naloxone emerging as a key harm reduction scheme. Globally, less than 10% of people who use drugs have access to treatment initiatives, including take-home naloxone. An optimum point of distribution of take-home naloxone is post-acute hospital care.
What This Paper Adds: There is role confusion regarding responsibility for the provision of take-home naloxone and patient education. This is exacerbated by inconsistent provision of training and education for healthcare professionals. Logistical or financial concerns are common and moral issues are prevalent with some healthcare professionals questioning the ethics of providing take-home naloxone. Stigma towards people who use drugs remains evident in some acute care areas which may impact the use of this intervention. Implications for practice/policy: Further primary research should examine what training and education methods are effective in improving the distribution of take-home naloxone in acute care. Education should focus on reduction of stigma towards people who use drugs to improve the distribution of take-home naloxone. Standardized care guidelines may ensure interventions are offered equally and take-home naloxone 'champions' could drive initiatives forward, with support from harm reduction specialists.
Reporting Method: This has adhered to the PRISMA reporting guidelines for systematic reviews.
Patient Or Public Contribution: No patient or public contribution.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jan.16181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Would provision of Take Home Naloxone Kits by Emergency Medical Services be perceived as acceptable to people at risk of opioid overdose? A qualitative study.
Prehosp Emerg Care
December 2024
Health Service Research, Swansea University Medical School.
Objectives: Take home naloxone kits can reduce mortality, but we know little about how they are perceived by people with lived experience of opioid use. Provision of naloxone in the community has been shown to significantly reduce mortality from opioid overdose. Currently, this is predominantly through drug treatment support services but expanding provision through other services might be effective in increasing kit take-up and mortality reduction.
View Article and Find Full Text PDFTake-Home Naloxone, Release From Jail, and Opioid Overdose-A Piece of the Puzzle.
JAMA Netw Open
December 2024
SEICHE Center for Health and Justice, Yale School of Medicine, New Haven, Connecticut.
Agent-Based Model of Combined Community- and Jail-Based Take-Home Naloxone Distribution.
JAMA Netw Open
December 2024
Decision and Infrastructure Sciences Division, Argonne National Laboratory, Lemont, Illinois.
Importance: Opioid-related overdose accounts for almost 80 000 deaths annually across the US. People who use drugs leaving jails are at particularly high risk for opioid-related overdose and may benefit from take-home naloxone (THN) distribution.
Objective: To estimate the population impact of THN distribution at jail release to reverse opioid-related overdose among people with opioid use disorders.
Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.
Subst Use Addctn J
November 2024
British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Article Synopsis
- The study investigates the impact of opioid agonist therapy (OAT) on methamphetamine and amphetamine use among individuals with opioid use disorder (OUD) in Canada, comparing buprenorphine/naloxone and methadone.
- Conducted over 24 weeks, data from a pan-Canadian trial highlighted that both treatments showed no significant effect on reducing methamphetamine/amphetamine use, as assessed through drug testing and self-reporting.
- Despite methamphetamine/amphetamine use being prevalent among participants, results indicated that neither treatment method led to notable changes in their usage patterns throughout the study period.
Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT.
Health Technol Assess
October 2024
Department of Medicine, Swansea University, Swansea, UK.
Background: Opioids kill more people than any other drug. Naloxone is an opioid antagonist which can be distributed in take-home 'kits' for peer administration (take-home naloxone).
Aim: To determine the feasibility of carrying out a definitive randomised controlled trial of take-home naloxone in emergency settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!